You are here: Industry Insights > Pacira

News List

Pacira BioSciences Announces Investment in Spine BioPharma americanpharmaceuticalreview
April 21, 2021
Pacira BioSciences, Inc., the industry leader in its commitment to non-opioid pain management and regenerative health solutions, announced a $3 million investment in Spine BioPharma in the form of a convertible note.
Pacira Receives EC Approval for EXPAREL for Postsurgical Pain americanpharmaceuticalreview
November 26, 2020
Pacira BioSciences announced the European Commission has granted marketing authorization for EXPAREL as a brachial plexus block or femoral nerve block for treatment of post-operative pain in adults, and as a field block for treatment of ...
Pacira Receives Positive CHMP Opinion for EXPAREL for Postsurgical Pain americanpharmaceuticalreview
September 27, 2020
Pacira BioSciences announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization for EXPAREL for postsurgical analgesia.
CHMP backs seven new meds in September meeting pharmatimes
September 22, 2020
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended seven new medicines for approval in its latest meeting.
Pacira Appoints Max Reinhardt as President contractpharma
June 20, 2019
Former Johnson & Johnson Executive brings extensive global experience leading multi-billion-dollar businesses to Pacira.
Pacira to buy MyoScience biospectrumasia
March 07, 2019
MyoScience currently markets the ioveraº system, a novel, FDA-approved non-opioid treatment that alleviates pain through a mechanism known as cryoanalgesia
Pacira to Acquire MyoScience, Adding FDA-approved ioveraº System for Non-opioid Pain Control pharmafocusasia
March 07, 2019
Pacira Pharmaceuticals, Inc. and MyoScience, Inc., a privately held medical technology company, today announced the signing of a definitive agreement for the acquisition of MyoScience by Pacira.
Pacira to Acquire MyoScience americanpharmaceuticalreview
March 06, 2019
Pacira Pharmaceuticals and MyoScience, a privately held medical technology company, announced the signing of a definitive agreement for the acquisition of MyoScience by Pacira.
Pacira CEO hopes for further expansion to US nerve block label pharmaphorum
April 16, 2018
US pharma Pacira hopes for a further expansion of the label for its nerve block Exparel covering surgical procedures throughout the body, after the FDA opted to expand its use to include shoulder surgery late last week.